Search

PR-15

PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

Inetetamab

It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

Phthalylsulfathiazole

It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

PR-104

Rosmarinic acid

Phentolamine

Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...

N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

Bumadizone

Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

Deramciclane

Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

Hydrocortisone butyrate